Aevi Genomic Medicine, Inc.
(NASDAQ : GNMX)

( )
GNMX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.19%178.420.7%$1156.79m
LLYEli Lilly & Co. -0.44%368.791.1%$1132.20m
MRKMerck & Co., Inc. -0.45%109.340.7%$1028.62m
PFEPfizer Inc. -0.27%51.000.9%$989.09m
ABBVAbbVie, Inc. -0.03%161.581.9%$866.05m
BMYBristol-Myers Squibb Co. 0.30%81.111.1%$773.98m
AZNAstraZeneca Plc -0.42%68.051.0%$356.60m
HZNPHorizon Therapeutics Plc 1.62%102.515.4%$314.21m
IDXXIDEXX Laboratories, Inc. 0.00%439.173.9%$229.98m
CTLTCatalent, Inc. 0.02%52.241.9%$213.67m
GSKGSK Plc 0.19%35.100.3%$190.10m
NVSNovartis AG -0.27%89.570.2%$185.83m
NVONovo Nordisk A/S -0.15%125.940.1%$172.56m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%220.258.0%$161.43m
RGENRepligen Corp. 0.00%188.176.7%$134.32m

Company Profile

Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.